Innovent bio announced on August 8, 2024 that its product revenue in the second quarter of 2024 exceeded RMB 2 billion, a year-on-year increase of about 50%. This strong growth is due to the company's rich product portfolio, strong brand, extensive coverage and access to the national medical insurance catalog, and the ability to meet the diverse needs of patients for innovative drugs. The company's flagship product, Tyvyt® (sintilimab injection), and other major products continue to sell strongly, and the market performance of new products has also accelerated, making a significant contribution to the company's revenue. Innovent bio is committed to developing the tumor field and comprehensive product line, including cardiovascular and metabolic, autoimmunity and ophthalmology areas, as a key...Show More

Innovent bio announced on August 8, 2024 that its product revenue in the second quarter of 2024 exceeded RMB 2 billion, a year-on-year increase of about 50%. This strong growth is due to the company's rich product portfolio, strong brand, extensive coverage and access to the national medical insurance catalog, and the ability to meet the diverse needs of patients for innovative drugs. The company's flagship product, Tyvyt® (sintilimab injection), and other major products continue to sell strongly, and the market performance of new products has also accelerated, making a significant contribution to the company's revenue. Innovent bio is committed to developing the tumor field and comprehensive product line, including cardiovascular and metabolic, autoimmunity and ophthalmology areas, as a key driver of long-term growth. Currently, the company has 10 products approved for marketing, 4 varieties are under review by the National Medical Products Administration, 4 new drug molecules have entered phase III or critical clinical research stage, and approximately 18 new molecules have entered clinical research. The company said that its innovative pipeline assets are diverse and have broad market potential, providing a solid foundation for long-term sustainable growth. The financial data mentioned in the announcement has not been audited or reviewed by an external auditor and is for reference only for investors.